Are you addicted to food? Learn whether your BRAIN is BLOCKING you from losing weight! Join the ranks of people who have collectively lost 133,000 pounds in the past two years, just by discovering how their brain is wired to …
Leveraging existing relationships with friends and family may be a more effective way to improve patients’ health and encourage new healthy habits and behaviours than increasing interactions with physicians or other clinicians. A Practice Management Article.
Lately some Ted talk discussions, led me to quickly download a book, “ Daring Greatly” by B Brown. No doubt this is a great book that actually helps understand not alone, how we behave, but also how we think and analyse situations around us. But there is More…..
Oncology is the study of tumors, both benign (noncancerous) and malignant (cancerous). An oncologist is a specialist in the diagnosis, treatment, and prevention of tumors or cancers.
“The signs and symptoms of cancer are manifestations of how cancer cells replace the functions of healthy tissue. Some examples include anorexia (lack of appetite), bruising, leukocytosis (slight increase of white blood cells), fatigue, cachexia (wasting), and thrombocytopenia (deficiency of clotting cells).”
You certainly have every right to keep your thoughts to yourself; however, what you withhold from your oncologist may interfere with reaching your goal of being cancer-free. If you are unhappy with us or our staff, please speak out. We would not be in this field if we did not want to improve our skills. If you feel dissatisfied with the consultation, share your frustrations with us. Remember—you are the most important person in the room. You are the one who deserves our respect and needs our encouragement. Your future, with you in it alive and well, is our mission. It would be deplorable if mistrust, confusion, or anger festered to the point of hampering your remission or even your peace of mind. In order for success to occur, you and your oncologist must journey together in a partnership of complete honesty. Speak now, tomorrow, and always your mind.
Immigration to the U.S. may result in increased smoking in Latino and Asian women, according to new research from sociologists at Rice University, Duke University and the University of Southern California.
The study, “Gender, Acculturation and Smoking Behavior Among U.S. Asian and Latino Immigrants,” examines smoking prevalence and frequency among Asian and Latino U.S. immigrants. The research focuses on how gender differences in smoking behavior are shaped by aspects of acculturation and the original decision to migrate. The study was published in the April issue of the journal Social Science & Medicine and is available online.
New Companies Join Cancer Research UK Consortium
|Published: Thursday, December 11, 2014
Last Updated: Thursday, December 11, 2014
|Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, its commercial arm, Cancer Research Technology and Abcodia.|
|The decision follows completion of a pilot phase to evaluate leading technologies for their ability to discover biomarkers that can detect cancer in its earliest stages, long before symptoms appear, when treatment is most likely to be effective. The technologies were tested against serum samples selected from a biobank of more than five million serum samples, collected from women as part of the UKCTOCS trial, to which Abcodia has exclusive commercial access.
Based on these findings, the three companies involved will be Caprion which specialises in proteomics, Asuragen which uses next-generation sequencing to find circulating microRNAs, and the AIT Austrian Institute of Technology using its tumour auto-antibodies platform.
This next stage of the programme will focus on identifying biomarkers for colorectal, lung, oesophageal and pancreatic cancers, chosen because of the limited availability of screening tests for these cancers and patients’ poor survival when diagnosed at a late stage.
Dr Julie Barnes, chief executive of Abcodia, said: “We are excited to work with these world leading companies to bring their cutting edge technology to this endeavour. The application of such technologies to biomarker discovery in longitudinal samples donated before the clinical presentation of cancer is a real innovation and has the potential to make a real difference to the field of early cancer detection.”
Professor Ian Jacobs, vice president at the University of Manchester, principal investigator of UKCTOCS and one of the founders of Abcodia, said: “Cancers that are diagnosed at a later stage are much more difficult to manage, so I am delighted to see the progress that this consortium is making. The experiments aimed at identifying biomarkers that could form simple, non-invasive tests for early cancer detection represent an ideal use of the biobank developed through UKCTOCS.”
Dr Keith Blundy, chief executive of Cancer Research Technology, said: “After a successful pilot, we are delighted to be able to bring additional technological capability into this collaborative effort, to add to the clinical, scientific and commercial expertise of existing partners. The biobank derived from UKCTOCS is providing us with the opportunity, through this initiative, to potentially unlock a future in which thousands of cancer cases could be detected and treated before symptoms emerge.”
NEW DELHI: There’s good news for patients. Drug pricing regulator NPPA announced cap on prices of over 25 drugs, including painkillers and antibiotics, which will lead to reduction in their costs over the next few weeks.
The price regulator in a notification issued on December 10, fixed prices of formulations which join a list of 348 essential medicines that were placed under price control. The new drugs on which caps were issued include commonly-used antibiotics and painkillers, as well as medicines used for treating cancer and skin disorders.
The NPPA notification mentions a total of 52 drugs, including those with specific dosage strengths which were till now not under the purview. The latest addition brings the total market size of medicines under price control to nearly Rs 125 crore, according to market research firm AIOCD AWACS. The wide-ranging price cuts will impact both domestic and foreign companies.
The NPPA notification, an industry expert explained, also includes price changes which will be extended on dosage strengths of molecules which were till now not under price control. It said it has fixed/revised the prices in respect of 52 formulation packs — both ceiling and retail price packs under DPCO, 2013. Price caps on some of these drugs only apply to specific companies, it added
Earlier efforts by the NPPA to bring down prices of essential drugs for diseases like cancer, have been strongly opposed. In July, the NPPA in a rare invocation of the lesser-used provision had fixed prices of 50 antidiabetic and cardiovascular medicines. This was the first time that the government had brought drugs, outside the national list of essential medicines, under price control.
The move had triggered of a series of protests and lawsuits from the industry against the drug pricing regulator, as they feared more such action.
Finally, in September this year the government had withdrawn certain powers of the drug pricing regulator that allowed it to cap prices of widely-prescribed anti-diabetes, cancer, HIV, tuberculosis and cardiac medicines.